[an error occurred while processing this directive] | [an error occurred while processing this directive]
Analysis of long-term survival outcomes and late radiation toxicity of 132 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy
Fang Zengyi1,2, Wu Zifei2, Wu Chuan2, Luo Cheng2, Gao Mingquan3, Lai Xin3, Luo Liping4, Wang Weidong1,2, Lang Jinyi2
1School of Clinical Medicine, Southwest Medical University, Luzhou 646000, China; 2Laboratory of Sichuan Cancer Hospital, Chengdu 610041, China; 3School of Medicine, University of Electronic Science and Technology of China, Chengdu 611731, China; 4Key Laboratory of Radiation Oncology in Sichuan Province, Chengdu 610041, China
AbstractObjective To retrospectively analyze the long-term survival (10-15 years) and late toxicity of nasopharyngeal carcinoma (NPC) patients after intensity-modulated radiotherapy (IMRT), aiming to provide reference for the optimal treatment of NPC. Methods 132 patients with NPC who were treated with IMRT in Sichuan Cancer Hospital from 2003 to 2009 were recruited. Among them, 3 patients were classified as stage Ⅰ, 22 cases of grade Ⅱ, 61 cases of grade Ⅲ, 43 cases of ⅣA and 3 cases of ⅣB, respectively. The median dose was 73.37Gy (66 to 85Gy), divided into 33 times. Twenty patients received radiotherapy alone, 112 cases of concurrent radiochemotherapy. The survival rate was calculated by Kaplan-Meier method and log-rank test. Univariate prognostic analysis was performed. Cox model was used to conduct multivariate prognostic analysis. The late radiation toxicity was evaluated by RTOG/EORTC criteria. Results The median follow-up duration was 128 months (range, 3 to 191 months). The 10-and 15-year local control rates of NPC patients were 86.0% and 79.9%. The disease-free survival rates were 72.5% and 63.2%, and the overall survival (OS) rates were 65.2% and 57.1%. The local recurrence rate was 12.1%, and the distant metastasis rate was 16.7%. A total of 53 patients died, of whom 15 patients died of local recurrence, 20 patients died of distant metastasis and 18 patients died of other diseases (pneumonia, intracranial hemorrhage and accident, etc.). The 10-and 15-year non-tumor-related mortality rates were 11.3% and 13.6%. Univariate analysis showed that age, smoking habit, lactate dehydrogenase (LDH), T stage and clinical stage were the independent prognostic factors of OS in NPC patients. Multivariate analysis demonstrated that LDH, T stage and synchronous chemotherapy were the prognostic factors of OS in NPC patients. The incidence of gradeⅠ-Ⅱ late radiation injury (hearing impairment, dysphagia, dental caries and xerostomia) was 90.4%,and 8.5% for grade Ⅲ-Ⅳ late radiation injury (skin fibrosis, hearing impairment and radiation brain injury). Conclusions The 10-and 15-year OS of NPC patients treated with IMRT is relatively high. With the prolongation of survival, the non-tumor-related mortality rate is increased. Distant metastasis is the main cause of treatment failure. The main late injuries include grade Ⅰ/Ⅱ hearing impairment, dysphagia, dental caries and xerostomia.
Fund:National Key Research & Development Program (2017YFC0113904);Sichuan Key Research & Development Project (2017SZ0004)
Corresponding Authors:
Wang Weidong, Email:wwdwyl@sina.com;Lang Jinyi, Email:Langjy610@163.com
Cite this article:
Fang Zengyi,Wu Zifei,Wu Chuan et al. Analysis of long-term survival outcomes and late radiation toxicity of 132 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 653-658.
Fang Zengyi,Wu Zifei,Wu Chuan et al. Analysis of long-term survival outcomes and late radiation toxicity of 132 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 653-658.
[1] 梁锌,杨剑,高婷,等. 中国鼻咽癌流行概况[J]. 中国肿瘤,2016, 5(11):835-840. Liang X, Yang J, Gao T, et al. Nasopharynx cancer epidemiology in China[J]. China Cancer, 2016, 25(11):835-840. [2] 蒋朝阳,张涛,高辉,等.406例鼻咽癌患者颈部及Ⅴ区后缘间隙淋巴结转移的预后分析[J]. 中国肿瘤临床,2017,44(20):1019-1023. DOI:10.3969/j.issn.1000-8179.2017.20.631. Jiang CY, Zhang T, Gao H, el al. Prognosis of cervical and posterior to level V lymph node metastasis in 406 cases of nasopharyngeal carcinoma[J]. Chin J Clin Oncol, 2017,44(20):1019-1023. DOI:10.3969/j.issn.1000-8179.2017.20.631. [3] 赵充,肖巍魏,韩非,等.419例鼻咽癌患者调强放疗疗效和影响[J]. 中华放射肿瘤学杂志,2010, 19(3):191-196. DOI:10.3760/cma.j.issn.1004-4221.2010.03.005. Zhao C, Xiao WW, Han F, el al. Long-term outcome and prognostic of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy[J]. Chin J Radiat Oncol, 2010, 19(3):191-196. DOI:10.3760/cma.j.issn.1004-4221.2010.03.005. [4] Radiation Therapy Oncology GROUP. A phase Ⅱ study of concurrent chemoradiotherapy using three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT)+ bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancer[DB/OL][2011-03-05].http://rpc.mdanderson.org/rpc/credentialing/files. [5] Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer[J]. J Clin Oncol, 2003, 21(1):92-98. DOI:10.1200/JCO.2003.01.008. [6] Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11:a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7):845-852. DOI:10.1200/JCO.2012.43.6097. [7] Kam MKM, Teo Pml, Chau RMC, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy:the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2004, 60(5):1440-1450. DOI:10.1016/j.ijrobp.2004.05.022. [8] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):286-293. DOI:10.1016/j.radonc.2012.08.013. [9] Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience[J]. Int J Radiat Oncol Biol Phys, 2009, 75(5):1481-1486. DOI:10.1016/j.ijrobp.2009.01.018. [10] Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2):356-364. DOI:10.1016/j.ijrobp.2007.12.054. [11] Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4):1071-1078. DOI:10.1016/j.ijrobp.2008.12.015. [12] 田允铭,韩非,曾雷,等. 鼻咽癌调强放疗后长期生存结果及失败模式分析[J]. 中华放射肿瘤学杂志, 2018, 27(10):880-885. DOI:10.3760/cma.j.issn.1004-4221.2018.10.002. Tian YM, Han F, Zeng L, el al. Long-term survival outcome and failure pattern after intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2018, 27(10):880-885. DOI:10.3760/cma.j.issn.1004-4221.2018.10.002. [13] Wu LR, Liu Y T, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy:an analysis of 614 patients from a single center[J]. Oral Oncol, 2017, 69(1):26-32. DOI:10.1016/j.oraloncology.2017.03.015. [14] Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population:a meta-analysis of the phase Ⅲ randomized trials[J]. BMC Cancer, 2010, 10(1):558. DOI:10.1186/1471-2407-10-558. [15] Sun Y, Ma J, Lu TX, et al. Regulation for distribution of metastatic cervical lymph nodes of 512 cases of nasopharyngeal carcinoma[J]. Ai Zheng, 2004, 23(11 suppl):1523-1527. [16] Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma[J]. Eur J Cancer, 2013, 49(10):2356-2364. DOI:10.1016/j.ejca.2013.03.008. [17] 刘晓清,罗伟,刘孟忠,等.1093例初治鼻咽癌的疗效和预后分析[J]. 中华放射肿瘤学杂志,2008, 17(2):81-86. DOI:10.3321/j.issn:1004-4221.2008.02.001. Liu XQ, Luo W, Liu MZ, et al. Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2008, 17(2):81-86. DOI:10.3321/j.issn:1004-4221.2008.02.001. [18] 肖光莉,丘熹彬,王卫华,等. 鼻咽癌调强放疗长期疗效及预后分析[J]. 中华放射肿瘤学杂志,2012, 21(6):488-491. DOI:10.3760/cma.j.issn.1004-4221.2012.06.002. Xiao GL, Qiu XB, Wang WH, et al. Long-term outcome and prognostic factors of nasopharyngeal carcinoma treated by intensity modulated radiotherapy[J]. Chin J Radiat Oncol, 2012, 21(6):488-491. DOI:10.3760/cma.j.issn.1004-4221.2012.06.002. [19] 尹丽,郭文杰,解鹏,等. 局部复发鼻咽癌超分割IMRT的临床分析[J]. 中华放射肿瘤学杂志,2016, 25(9):917-922. DOI:10.3760/cma.j.issn.1004-4221.2016.09.002. Yin L, Guo WJ, Xie P, et al. Efficacy of intensity-modulated radiotherapy on patients with locally recurrent nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2016, 25(9):917-922. DOI:10.3760/cma.j.issn.1004-4221.2016.09.002. [20] 孔琳,张有望,吴永如,等. 鼻咽癌放疗后长期生存者晚期副反应研究[J]. 中华放射肿瘤学杂志,2006, 15(3):153-156. DOI:10.3760/j.issn:1004-4221.2006.03.001. Kong L, Zhang YW, Wu YR, et al. Late side reactions of long-term survivors after radiotherapy for nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2006, 15(3):153-156. DOI:10.3760/j.issn:1004-4221.2006.03.001.